Northeast Pharmaceutical Group Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.5% per year. Northeast Pharmaceutical Group's return on equity is 6.8%, and it has net margins of 4.3%.
Wichtige Informationen
35.5%
Wachstumsrate der Gewinne
33.8%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 10.9% |
Wachstumsrate der Einnahmen | 1.5% |
Eigenkapitalrendite | 6.8% |
Netto-Marge | 4.3% |
Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 30It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
Aug 07These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely
May 25Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05Aufschlüsselung der Einnahmen und Ausgaben
Wie Northeast Pharmaceutical Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Sep 24 | 7,973 | 347 | 2,056 | 108 |
30 Jun 24 | 7,905 | 380 | 2,066 | 108 |
31 Mar 24 | 7,829 | 346 | 2,270 | 101 |
31 Dec 23 | 8,243 | 358 | 2,573 | 97 |
30 Sep 23 | 8,643 | 442 | 2,839 | 146 |
30 Jun 23 | 8,895 | 373 | 3,031 | 146 |
31 Mar 23 | 8,810 | 352 | 2,913 | 152 |
01 Jan 23 | 8,809 | 350 | 2,789 | 160 |
30 Sep 22 | 8,609 | 202 | 2,727 | 106 |
30 Jun 22 | 8,555 | 151 | 2,752 | 102 |
31 Mar 22 | 8,478 | 129 | 2,776 | 93 |
31 Dec 21 | 8,145 | 99 | 2,711 | 83 |
30 Sep 21 | 8,003 | 37 | 2,613 | 62 |
30 Jun 21 | 7,671 | 14 | 2,530 | 61 |
31 Mar 21 | 7,465 | 71 | 2,458 | 69 |
31 Dec 20 | 7,384 | 12 | 2,453 | 74 |
30 Sep 20 | 7,659 | -1 | 2,751 | 76 |
30 Jun 20 | 7,833 | 113 | 2,784 | 74 |
31 Mar 20 | 8,026 | 97 | 2,901 | 73 |
31 Dec 19 | 8,220 | 174 | 3,014 | 64 |
30 Sep 19 | 7,898 | 214 | 2,880 | 137 |
30 Jun 19 | 7,828 | 198 | 2,823 | 154 |
31 Mar 19 | 7,622 | 200 | 2,724 | 148 |
31 Dec 18 | 7,467 | 195 | 2,581 | 145 |
30 Sep 18 | 7,102 | 196 | 2,443 | 73 |
30 Jun 18 | 6,659 | 196 | 2,214 | 72 |
31 Mar 18 | 6,204 | 160 | 1,987 | 62 |
31 Dec 17 | 5,676 | 119 | 1,740 | 58 |
30 Sep 17 | 5,271 | 98 | 1,470 | 26 |
30 Jun 17 | 5,176 | 60 | 1,416 | 0 |
31 Mar 17 | 5,016 | 39 | 1,318 | 0 |
31 Dec 16 | 4,814 | 24 | 1,236 | 0 |
30 Sep 16 | 4,581 | -156 | 1,204 | 0 |
30 Jun 16 | 4,122 | -295 | 1,204 | 0 |
31 Mar 16 | 4,031 | -358 | 1,223 | 0 |
31 Dec 15 | 3,834 | -384 | 1,153 | 0 |
30 Sep 15 | 4,006 | -194 | 1,078 | 0 |
30 Jun 15 | 4,092 | -77 | 1,009 | 0 |
31 Mar 15 | 4,223 | -8 | 1,039 | 0 |
31 Dec 14 | 4,333 | 87 | 1,077 | 0 |
30 Sep 14 | 4,260 | -27 | 1,224 | 0 |
30 Jun 14 | 4,199 | -56 | 1,226 | 0 |
31 Mar 14 | 4,022 | -77 | 1,178 | 0 |
31 Dec 13 | 3,871 | -167 | 1,130 | 0 |
Qualität der Erträge: 000597 has a large one-off gain of CN¥206.2M impacting its last 12 months of financial results to 30th September, 2024.
Wachsende Gewinnspanne: 000597's current net profit margins (4.3%) are lower than last year (5.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 000597's earnings have grown significantly by 35.5% per year over the past 5 years.
Beschleunigtes Wachstum: 000597's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 000597 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 000597's Return on Equity (6.8%) is considered low.